2019 Biotechnology Awards

6 GHP / 2019 Biotechnology Awards adapts to bring many of its clients the required expertise, drawing on its efforts for well over a decade in the quality and information security space. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards. Operating internationally and supporting a range of clients and service users in such an important market, MMS works hard to remain at the forefront of emerging market developments to ensure excellence at all times. The Regulatory Operations and Compliance Department at MMS completes an extensive, ongoing monthly review of all health authority websites in addition to actively reviewing real-time notifications of regulatory content updates. Once a month, all updated and/or new regulatory content, including guidelines and guidance for industry, is reviewed for relevance. If found pertinent, these updates are then distributed to colleagues within each of the departments for review. The Regulatory and Medical Writing and Safety Risk Management departments at MMS rely on the Technical Requirements Review Committee to analyze and evaluate the applicability and impact of the latest regulations and requirements on the work the firm undertakes. This approach ensures that the firm is able to offer cutting-edge solutions and support. As a result, MMS has embraced regulatory changes globally and invested in colleague training and technology to better support sponsors as its industry evolves. The company has been a pioneer in several key services, forging the way in Policy 0070 and other key transparency initiatives, leadership within organizations such as PhUSE, and plain lay summary programs. Seeking to build upon its current success, recently MMS partnered with the Julia Lab at MIT, Julia Computing, and the Center for Translational Medicine (CTM) at the University of Maryland School of Pharmacy, to develop the Health Analytics Collective. The timeline to market a new drug or medical device, from the point of discovery to U.S. Food and Drug Administration approval, can stretch to a decade. By pooling its industry experience and technology, a new health research supergroup led by the Julia Lab within the MIT Computer Science

http://innd.com/ http://www.mmsholdings.com/